Erasca presents Phase 1b dose escalation data from FLAGSHIP-1 for ERAS-601

Erasca presented promising initial Phase 1b dose escalation data from FLAGSHP-1 for ERAS-601 in combination with cetuximab in patients with advanced solid tumors as part of a poster presentation at the American Association for Cancer Research, AACR, Annual Meeting in Orlando, Florida. ERAS-601 is a potent, selective, oral small molecule SHP2 inhibitor with best-in-class potential. The poster is available online at Erasca.com/science/presentations. Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: A Phase I study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors. ERAS-601 in combination with cetuximab inhibits RAS/MAPK signaling at multiple nodes which is predicted to limit the development of treatment resistance and offer more robust synergistic anti-tumor activity over monotherapy alone. ERAS-601 in combination with cetuximab shows promising preliminary safety and tolerability with reversible and manageable treatment-related adverse events; Only grade 1 or 2 TRAEs occurred at or below the combination MTD for ERAS-601; ERAS-601 MTD was determined to be 40 mg BID 3/1 in combination with cetuximab administered every 2 weeks; Initial Phase 1b dose expansion data in HPV-negative HNSCC tumors is expected in H1 2024